Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
18.74
-0.15 (-0.79%)
Nov 13, 2026, 4:00 PM EST - Market closed
Denali Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21.38 | - | - | 330.53 | 108.46 | 48.66 | |
Revenue Growth | - | - | - | 204.74% | 122.89% | -85.50% |
Cost of Revenue | 413.58 | 418.78 | 396.44 | 423.88 | 358.73 | 265.35 |
Gross Profit | -392.2 | -418.78 | -396.44 | -93.35 | -250.27 | -216.69 |
Selling, General & Admin | 146.74 | 136.56 | 105.44 | 103.35 | 90.48 | 79.06 |
Research & Development | -8.43 | - | - | - | - | - |
Operating Expenses | 138.31 | 136.56 | 105.44 | 103.35 | 90.48 | 79.06 |
Operating Income | -530.51 | -555.34 | -501.88 | -196.7 | -340.74 | -295.75 |
Interest & Investment Income | 18.33 | 32.65 | 29.52 | 7.55 | 13.14 | 13.34 |
EBT Excluding Unusual Items | -512.19 | -522.69 | -472.36 | -189.15 | -327.61 | -282.41 |
Gain (Loss) on Sale of Investments | 5.36 | 10.25 | 35.12 | 43.95 | 1.64 | -8.75 |
Gain (Loss) on Sale of Assets | 194 | - | 14.54 | - | - | - |
Pretax Income | -314.32 | -512.44 | -422.71 | -145.19 | -325.97 | -291.16 |
Income Tax Expense | 0.1 | 0.1 | 0.07 | 0.03 | 0.02 | -0.58 |
Net Income | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58 |
Net Income to Common | -314.42 | -512.54 | -422.77 | -145.22 | -325.99 | -290.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 184 | 173 | 164 | 137 | 126 | 122 |
Shares Outstanding (Diluted) | 184 | 173 | 164 | 137 | 126 | 122 |
Shares Change | 7.68% | 4.97% | 19.73% | 9.43% | 3.30% | 7.83% |
EPS (Basic) | -1.70 | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
EPS (Diluted) | -1.70 | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -449.99 | -422.1 | -363.61 | -370.93 | -262.55 | -219.89 |
Free Cash Flow Per Share | -2.44 | -2.44 | -2.21 | -2.70 | -2.09 | -1.81 |
Gross Margin | - | - | - | -28.24% | -230.74% | - |
Operating Margin | -2481.12% | - | - | -59.51% | -314.16% | -607.78% |
Profit Margin | -1470.50% | - | - | -43.94% | -300.56% | -597.15% |
Free Cash Flow Margin | -2104.54% | - | - | -112.22% | -242.06% | -451.88% |
EBITDA | -514 | -540.53 | -492.89 | -187.87 | -330.36 | -287.16 |
EBITDA Margin | - | - | - | -56.84% | - | - |
D&A For EBITDA | 16.52 | 14.81 | 8.99 | 8.83 | 10.38 | 8.59 |
EBIT | -530.51 | -555.34 | -501.88 | -196.7 | -340.74 | -295.75 |
EBIT Margin | - | - | - | -59.51% | - | - |
Revenue as Reported | 21.38 | - | - | 330.53 | 108.46 | 48.66 |